Vir Biotechnology has officially closed its exclusive worldwide license agreement with Sanofi, following the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Act. The agreement grants Vir access to three clinical-stage masked T-cell engagers (TCEs), each with potential applications in oncology, as well as Sanofi’s PRO-XTEN™ masking platform, designed to target cancer and infectious diseases. Key Sanofi employees with expertise in TCE development will also transition to Vir, enhancing the company’s capabilities in these areas.
The three licensed assets include:
SAR446309, a HER2-targeted TCE in phase 1 clinical trials for HER2+ tumors like breast and colorectal cancer.
SAR446329, a PSMA-targeted TCE in phase 1 trials for castration-resistant prostate cancer.
SAR446368, an EGFR-targeted TCE expected to begin phase 1 studies in early 2025 for EGFR-expressing tumors.
The PRO-XTEN™ platform allows for the selective activation of drug candidates within tumor tissues, reducing off-target effects and enhancing the safety of therapies. This collaboration positions Vir to advance its oncology and infectious disease pipeline, with further details on development plans to be shared at its upcoming R&D Day in November.
Click here to read the original news story.